Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467205 | 0.82 | MAPT (0.64) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL4864755 | 0.82 | MAPT (0.64) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL4140582 | 0.77 | GAA (0.58) | CYP3A4TSHRMAPTPOLBALDH1A1 | |
| SCHEMBL6844598 | 0.77 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL27917074 | 0.75 | CA12 (0.67) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL4221613 | 0.74 | RECQL (0.77) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL1660322 | 0.74 | RECQL (0.77) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL30506314 | 0.74 | RECQL (0.77) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL20082281 | 0.74 | CYP2C9 (0.61) | CYP2C9CYP2C19CYP1A2CYP3A4TSHR | |
| SCHEMBL10033601 | 0.74 | CA1 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | claimed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | claimed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | CYP2C9 3735/4885CYP2C19 3645/4885CYP1A2 4114/4885 |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | CYP2C9 3735/4885CYP2C19 3645/4885CYP1A2 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.